By Counterforce Health Team in Nucala (mepolizumab) —

Blue Cross Blue Shield Illinois Coverage Criteria for Nucala (Mepolizumab): What Counts as "Medically Necessary"?

Quick Answer: Getting Nucala Covered by Blue Cross Blue Shield in Illinois

Blue Cross Blue Shield of Illinois requires prior authorization for Nucala with specific medical necessity criteria: blood eosinophil count ≥150 cells/μL (recent) or ≥300 cells/μL (past year), documented severe eosinophilic asthma despite 3+ months of high-dose inhaled corticosteroids plus controller therapy, and prescription by a pulmonologist, allergist, or immunologist. First step: Have your specialist submit a PA request with lab results, medication history, and exacerbation records through the BCBSIL provider portal. Appeals must be filed within 180 days, with external review available through the Illinois Department of Insurance within 4 months of denial.

Table of Contents

BCBSIL Policy Overview

Blue Cross Blue Shield of Illinois (BCBSIL) covers Nucala under their specialty pharmacy benefit with mandatory prior authorization for all plan types—HMO, PPO, and POS. The drug typically requires Tier 4 specialty status on most formularies, meaning higher copays and stricter oversight.

Key Policy Elements:

  • Prior authorization required for all indications
  • Step therapy may apply (benralizumab or dupilumab first)
  • Specialist prescribing requirement
  • 6-12 month authorization periods with renewal requirements
  • Appeals allowed within 180 days of denial

Find current policies through the BCBSIL provider portal or member services. Policy details can vary between employer groups, so always verify your specific plan's formulary and coverage terms.

FDA Indication Requirements

Nucala is FDA-approved for multiple conditions, but BCBSIL coverage focuses primarily on:

Covered Indications:

  • Severe eosinophilic asthma (ages 6+): Add-on maintenance therapy
  • Eosinophilic granulomatosis with polyangiitis (EGPA) (adults)
  • Hypereosinophilic syndrome (HES) (ages 12+)
  • Chronic rhinosinusitis with nasal polyps (CRSwNP) (adults 18+)

Off-Label Use: BCBSIL may consider off-label use with exceptional documentation, including peer-reviewed literature and specialist attestation. However, on-label indications receive priority in coverage decisions.

The FDA prescribing information provides complete indication details and dosing guidelines that align with BCBSIL's coverage criteria.

Step Therapy & Medical Exceptions

BCBSIL often requires patients to try alternative biologics before approving Nucala, particularly benralizumab (Fasenra) or dupilumab (Dupixent) for eosinophilic asthma.

Step Therapy Requirements:

  • Trial of preferred biologic for minimum 3-6 months
  • Documentation of inadequate response or intolerance
  • Objective measures of treatment failure (ACT scores, exacerbations)

Medical Exception Pathways:

  • Contraindications: Document specific medical reasons why preferred agents cannot be used
  • Previous failure: If tried outside current insurance, provide detailed records
  • Specialist recommendation: Pulmonologist/allergist attestation for Nucala as first-line

Documentation for Exceptions:

  • Prior therapy summary with dates, doses, duration
  • Reason for discontinuation (efficacy vs. safety)
  • Clinical rationale for Nucala specifically
  • Supporting literature if applicable

Quantity and Frequency Limits

BCBSIL enforces strict quantity limits aligned with FDA dosing:

Dosing by Indication:

Indication Age Group Dose Frequency
Severe Asthma 6-11 years 40 mg SC Every 4 weeks
Severe Asthma ≥12 years 100 mg SC Every 4 weeks
EGPA Adults 300 mg SC Every 4 weeks
HES ≥12 years 300 mg SC Every 4 weeks
CRSwNP ≥18 years 100 mg SC Every 4 weeks

Quantity Restrictions:

  • Maximum: One dose per 28-day period
  • No dose escalation beyond FDA recommendations
  • 300 mg doses given as three separate 100 mg injections

Renewal Requirements:

  • Initial authorization: 6-12 months
  • Renewal documentation: Clinical improvement evidence
  • Ongoing monitoring: Eosinophil counts, symptom control

Required Diagnostic Documentation

BCBSIL requires specific laboratory and clinical evidence to establish medical necessity:

Essential Lab Values:

  • Blood eosinophil count: ≥150 cells/μL within 6 weeks OR ≥300 cells/μL within 12 months
  • Lab timing: Recent values preferred; historical acceptable with clinical correlation
  • Reference ranges: Include normal values from testing laboratory

Clinical Documentation:

  • Asthma severity: ACT scores, ACQ scores, or equivalent validated tools
  • Exacerbation history: ≥2 systemic corticosteroid courses in past 12 months
  • Current control status: Despite optimized therapy
  • Specialist evaluation: Pulmonology, allergy, or immunology consultation
Tip: Submit lab results with clear dates and reference ranges. BCBSIL reviewers need to verify eosinophil thresholds quickly during the authorization process.

IgE Testing: Not required for Nucala approval (unlike omalizumab), but may be included if available to support overall allergic asthma phenotyping.

Site of Care & Specialty Pharmacy

Nucala administration through BCBSIL follows specific routing requirements:

Administration Sites:

  • Self-injection at home: Preferred for stable patients
  • Physician office: Required for initial doses or complex patients
  • Specialty pharmacy delivery: Through BCBSIL-approved vendors

Specialty Pharmacy Network:

  • Coverage limited to in-network specialty pharmacies
  • Prior authorization applies regardless of administration site
  • Out-of-network administration may require additional approvals

Logistics:

  • Subcutaneous injection only (no IV formulation)
  • Temperature-controlled shipping required
  • Patient training for self-administration

Starting in 2025, some self-administered specialty drugs may shift to pharmacy benefit review, so verify current routing with BCBSIL before submission.

Evidence to Support Medical Necessity

Strong prior authorization requests include evidence from multiple sources:

Clinical Guidelines:

  • GINA Guidelines: Global Initiative for Asthma recommendations for severe asthma management
  • ATS/ERS Guidelines: American Thoracic Society/European Respiratory Society severe asthma guidelines
  • AAAAI Position Statements: American Academy of Allergy, Asthma & Immunology biologic use guidance

Peer-Reviewed Literature:

  • Pivotal clinical trials (MENSA, MUSCA studies for asthma)
  • Real-world effectiveness studies
  • Safety data from post-marketing surveillance

Regulatory Support:

Sample Medical Necessity Documentation

Template Structure for BCBSIL Submission:

"Patient is a [age]-year-old with severe persistent eosinophilic asthma despite optimized controller therapy. Blood eosinophil count of [value] cells/μL on [date] meets criteria for eosinophilic phenotype. Despite 6 months of high-dose fluticasone/salmeterol [dose] plus montelukast [dose], patient experienced [number] exacerbations requiring systemic corticosteroids in the past 12 months, with [number] emergency department visits. Current ACT score is [value], indicating poor control. Previous trial of [alternative biologic] for [duration] resulted in [outcome/reason for discontinuation]. Based on eosinophilic phenotype, treatment history, and current guidelines, mepolizumab 100 mg subcutaneously every 4 weeks is medically necessary to achieve asthma control and prevent severe exacerbations."

Required Attachments:

  • Recent eosinophil lab results
  • Medication history with dates and doses
  • Exacerbation documentation (ER visits, steroid prescriptions)
  • Specialist consultation notes
  • Previous biologic trial records (if applicable)

Appeals Process and Timelines

When BCBSIL denies Nucala coverage, Illinois residents have strong appeal rights:

Internal Appeal Process:

  1. Submit within 180 days of denial notice
  2. Timeline: BCBSIL responds within 15 business days (pre-service) or 30 days (post-service)
  3. Documentation: Include all supporting clinical evidence
  4. Expedited option: Available for urgent medical situations (24-48 hour response)

External Review (Illinois Department of Insurance):

  1. Eligibility: After internal appeal denial
  2. Filing deadline: Within 4 months of final internal denial
  3. Process: Independent Review Organization (IRO) with specialist physician
  4. Timeline: Decision within 30 days of complete submission
  5. Cost: Free to patients; insurers pay IRO fees

Contact Information:

  • Illinois Department of Insurance: External Review Program
  • Consumer Helpline: 877-527-9431
  • Illinois Attorney General Health Care Bureau: 877-305-5145
Note: Illinois has a shorter external review filing window (4 months) compared to some states. Act promptly after internal appeal denials.

Common Denial Reasons & Solutions

Denial Reason Solution Documentation Needed
Eosinophil count too low Submit recent labs showing ≥150 cells/μL Lab results with date and reference range
Inadequate prior therapy Document 3+ months high-dose ICS + controller Medication history with doses and duration
Missing specialist requirement Obtain pulmonology/allergy consultation Specialist consultation notes and prescription
Step therapy not completed Trial preferred biologic or document exception Prior therapy records or contraindication documentation
Insufficient exacerbation history Provide steroid burst records or ER visits Prescription records, hospital discharge summaries

Common Mistakes to Avoid:

  • Submitting outdated eosinophil counts (>12 months old)
  • Missing controller medication details
  • Incomplete prior therapy documentation
  • Non-specialist prescribing without consultation

Counterforce Health specializes in turning these denials into successful appeals by identifying specific policy gaps and crafting targeted rebuttals with the right clinical evidence. Their platform helps patients and providers navigate complex prior authorization requirements more effectively.

FAQ

How long does BCBSIL prior authorization take for Nucala? Standard review takes up to 15 business days for pre-service requests. Expedited review (for urgent cases) provides decisions within 24-48 hours. Submit complete documentation to avoid delays.

What if Nucala isn't on my formulary? Request a formulary exception with medical necessity documentation. Include evidence that covered alternatives are inappropriate or have failed. BCBSIL must review exception requests even for non-formulary drugs.

Can I appeal if I've been stable on Nucala and switch plans? Yes. Illinois step therapy laws may protect patients stable on current therapy from repeating failed trials. Document current stability and previous authorization history.

Does BCBSIL cover Nucala for off-label uses? Potentially, with exceptional documentation including peer-reviewed literature, specialist recommendation, and evidence that FDA-approved alternatives are unsuitable.

What's the difference between internal and external appeals? Internal appeals are reviewed by BCBSIL staff. External appeals use independent physician reviewers through the Illinois Department of Insurance. External review decisions are binding on the insurer.

How do I find BCBSIL's current Nucala policy? Check the BCBSIL provider portal or request current medical policies from member services. Policies update annually.

Can my doctor request a peer-to-peer review? Yes. If initially denied, prescribing physicians can request to speak directly with BCBSIL medical directors to discuss clinical rationale and answer questions about the case.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies change frequently—always verify current requirements with Blue Cross Blue Shield of Illinois and consult healthcare providers for medical decisions.

For additional assistance with insurance appeals and prior authorizations, Counterforce Health provides specialized support in converting denials into evidence-backed appeals that align with payer-specific requirements.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.